罗特西普治疗非输血依赖型β地中海贫血的贫血(BEYOND):一项2期、随机、双盲、多中心、安慰剂对照试验
BEYOND试验在6个国家12个中心纳入145例非输血依赖型β地中海贫血成人患者,按2:1随机接受罗特西普(n=96)或安慰剂(n=49),每3周皮下注射一次、共48周。罗特西普组74例(77%)在第13-24周连续12周内无需输血即达到血红蛋白平均升高≥1.0 g/dL,安慰剂组为0例(共同风险差77.1,95%CI 68.7-85.5;P<0.0001)。罗特西普组严重不良事件比例低于安慰剂组(11例[12%] vs 12例[25%]),研究期间未报告血栓栓塞事件或死亡。
要点
- 罗特西普组77%达到主要终点,安慰剂组为0%,共同风险差77.1(95%CI 68.7-85.5;P<0.0001)。
- 罗特西普组严重不良事件11例(12%),低于安慰剂组的12例(25%)。
- 罗特西普最常见治疗中出现的不良事件为骨痛(37%)、头痛(30%)和关节痛(29%)。
核心结论
- 罗特西普是成人非输血依赖型β地中海贫血的潜在治疗选择,该人群获批的有效治疗选择稀少。
研究设计与样本
- 2期、随机、双盲、多中心、安慰剂对照试验,在6个国家12个中心开展。
- 2018年2月5日至2019年10月14日筛查160例,145例随机分配至罗特西普组(n=96)或安慰剂组(n=49),按2:1分配。
- 纳入年龄≥18岁、确诊β地中海贫血或血红蛋白E/β地中海贫血、基线血红蛋白≤10.0 g/dL且非输血依赖的患者。
- 罗特西普或安慰剂每3周皮下注射一次、共48周,罗特西普起始1.0 mg/kg,可滴定至1.25 mg/kg或按毒性或血红蛋白过度升高而减量。
- 主要终点为第13-24周内连续12周平均血红蛋白较基线升高≥1.0 g/dL且无需输血。
主要发现
- 罗特西普组74/96例(77%)达到主要终点,安慰剂组0例,共同风险差77.1(95%CI 68.7-85.5;P<0.0001)。
- 罗特西普组严重不良事件11例(12%),安慰剂组12例(25%)。
- 罗特西普组最常见治疗中出现的不良事件为骨痛35例(37%)、头痛29例(30%)和关节痛28例(29%)。
- 研究期间未报告血栓栓塞事件或死亡。
- 145例中女性82例(57%)、男性63例(43%);亚裔44例(30%)、白人87例(60%)、其他种族14例(10%)。
临床怎么用
- 原文结论认为罗特西普是成人非输血依赖型β地中海贫血的潜在治疗选择,该人群获批的有效治疗选择稀少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with non-transfusion-dependent β-thalassaemia, haemoglobin concentrations lower than 10 g/dL are associated with a higher risk of morbidity, mortality, and impaired quality of life. No drugs are specifically approved for anaemia management in patients with non-transfusion-dependent β-thalassaemia, other than transfusion therapy administered infrequently in accordance with patients' needs. We assessed the efficacy and safety of luspatercept versus placebo in patients with non-transfusion-dependent β-thalassaemia. METHODS: We did a phase 2, randomised, double-blind, multicentre, placebo-controlled trial in 12 centres in six countries (Thailand [n=1], Lebanon [n=1], Greece [n=2], Italy [n=5], the UK [n=1], and the USA [n=2]). Eligible patients were aged 18 years or older, had confirmed diagnosis of β-thalassaemia or haemoglobin E/β-thalassaemia (concomitant α-globin deletion, mutation, or duplication were allowed), and a baseline haemoglobin concentration of 10·0 g/dL or lower. All patients were non-transfusion-dependent. Patients were randomly assigned (2:1) to luspatercept or placebo using an interactive response technology system and stratified by baseline haemoglobin concentration (≥8·5 g/dL vs <8·5 g/dL) and baseline Non-Transfusion-Dependent β-thalassaemia-Patient-Reported Outcome Tiredness/Weakness domain score (≥3 vs <3). All patients, study site staff, and sponsor representatives (who reviewed the data), except for designated individuals, were masked to drug assignment until the time the study was unblinded. Luspatercept or placebo was given once subcutaneously every 3 weeks for 48 weeks in the double-blind treatment period. Luspatercept was started at 1·0 mg/kg with titration up to 1·25 mg/kg, or reduction in the event of toxicity or excessive haemoglobin concentration increase. The primary endpoint was achievement of an increase from baseline of 1·0 g/dL or higher in mean haemoglobin concentration over a continuous 12-week interval during weeks 13-24, in the absence of transfusions. The primary efficacy and safety analyses were done in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT03342404, and is ongoing. FINDINGS: Between Feb 5, 2018, and Oct 14, 2019, 160 patients were screened for eligiblity, of whom 145 were randomly assigned to luspatercept (n=96) or placebo (n=49). 82 (57%) patients were female and 63 (43%) were male. 44 (30%) patients were Asian, 87 (60%) were White, and 14 (10%) identified as another race. The study met its primary endpoint: 74 (77%) of 96 patients in the luspatercept group and none in the placebo group had an increase of at least 1·0 g/dL in haemoglobin concentration (common risk difference 77·1 [95% CI 68·7-85·5]; p<0·0001). The proportion of patients with serious adverse events was lower in the luspatercept group than in the placebo group (11 [12%] vs 12 [25%]). Treatment-emergent adverse events most commonly reported with luspatercept were bone pain (35 [37%]), headache (29 [30%]), and arthralgia (28 [29%]). No thromboembolic events or deaths were reported during the study. INTERPRETATION: Luspatercept represents a potential treatment for adult patients with non-transfusion-dependent β-thalassaemia, for whom effective approved treatment options are scarce. FUNDING: Celgene and Acceleron Pharma.
引用
- Taher AT, Cappellini MD, Kattamis A, et al. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial. Lancet Haematol. 2022. PMID: 36007538. doi:10.1016/S2352-3026(22)00208-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。